Retender radar: UK public contracts ending soon

Every contract on Find a Tender with a published end date in the future, one row per contract (lot). A contract ending is a procurement starting — unless the buyer uses a published extension option, which the row shows. Frameworks and DPS are marked: what ends there is the vehicle, not one supplier’s contract.

When contracts end · Medical equipments, pharmaceuticals
i

When contracts here run out.

Published contracts by their end date. No end date, not counted.

A likely retender, not a certain one.

902 contracts end within 24 months, 1,006 in total · £90m published GBP value, exc. VAT, in the next 12 months (framework ceilings included, not a spend forecast).

  1. Next 3 months22
  2. 3–6 months277
  3. 6–12 months292
  4. 12–24 months311

By sector, next 12 months
i

When contracts here run out.

Published contracts by their end date. No end date, not counted.

A likely retender, not a certain one.

Contracts ending in the chosen window, by category.

CPV division of the procedure; a contract with several divisions counts in each.

Contracts ending in the next 12 months

Showing 351–375

  1. Ends · in 199 daysFramework re-let

    Factor XIII - Recombinant

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Novo Nordisk

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  2. Ends · in 199 daysFramework re-let

    Standard Half-life Recombinant Factor VIII

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Takeda UK Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  3. Ends · in 199 daysFramework re-let

    Von willebrands factor / Factor VIII

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Octapharma Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  4. Ends · in 199 daysFramework re-let

    Von willebrands factor / Factor VIII

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: CSL BEHRING UK LIMITED

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  5. Ends · in 199 daysFramework re-let

    Von willebrands factor - Plasma Derived

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: LFB

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  6. Ends · in 199 daysFramework re-let

    Von willebrands factor - Recombinant

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Takeda UK Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  7. Ends · in 199 daysFramework re-let

    Fibrinogen Concentrate

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: LFB

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  8. Ends · in 199 daysFramework re-let

    Fibrinogen Concentrate

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Octapharma Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  9. Ends · in 199 daysFramework re-let

    Fibrinogen Concentrate

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: CSL BEHRING UK LIMITED

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  10. Ends · in 199 daysFramework re-let

    Prothrombin Complex dried

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Takeda UK Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  11. Ends · in 199 daysFramework re-let

    Prothrombin Complex dried

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Octapharma Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  12. Ends · in 199 daysFramework re-let

    Prothrombin Complex dried

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: CSL BEHRING UK LIMITED

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  13. Ends · in 199 daysFramework re-let

    Standard Half-life Recombinant Factor VIII

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Octapharma Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  14. Ends · in 199 daysFramework re-let

    Protein C Concentrate

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Takeda UK Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  15. Ends · in 199 daysFramework re-let

    Fresh Frozen Plasma (all blood groups)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Octapharma Limited

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  16. Ends · in 199 daysFramework re-let

    Enhanced Half-life Recombinant Factor VIII

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Novo Nordisk

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  17. Ends · in 199 daysFramework re-let

    Enhanced Half-life Recombinant Factor VIII

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Sobi (Swedish Orphan Biovitrum Ltd)

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  18. Ends · in 199 daysFramework re-let

    Emicizumab

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Roche Products Ltd

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  19. Ends · in 199 daysFramework re-let

    Eftrenonacog alfa (rFIX EHL)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Sobi (Swedish Orphan Biovitrum Ltd)

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  20. Ends · in 199 daysFramework re-let

    albutrepenonacog alfa (rFIX EHL)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: CSL BEHRING UK LIMITED

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  21. Ends · in 199 daysFramework re-let

    nonacog beta pegol (rFIX EHL)

    NHS England · NHS & health · Nationwide (UK)

    Incumbent: Novo Nordisk

    • Pharmaceutical products
    Contract value
    £1ceiling for the whole framework
    Annual run-rate
    —ceiling, not a run-rate
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-043b0e
  22. Ends · in 199 days

    Varicella-zoster immunoglobulin (VZIG) 2025

    Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · NHS & health · Nationwide (UK)

    Incumbent: BIO PRODUCTS LABORATORY LIMITED

    • Immune sera and immunoglobulins
    Contract value
    £1
    Annual run-rate
    —start date not published
    Term
    Ends 30 Apr 2027 · start not published
    Reference
    ocds-h6vhtk-047b9e
  23. Ends · in 199 days

    Varicella-zoster immunoglobulin (VZIG) 2025

    Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · NHS & health · Nationwide (UK)

    Incumbent: BIO PRODUCTS LABORATORY LIMITED

    • Immune sera and immunoglobulins
    Contract value
    £1
    Annual run-rate
    £1value ÷ published term
    Term
    1 May 2025 → 30 Apr 2027 · 1.9 yrs
    Reference
    ocds-h6vhtk-047b9e
  24. Ends · in 199 days

    Varicella-zoster immunoglobulin (VZIG) 2025

    Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · NHS & health · Nationwide (UK)

    Incumbent: Grifols UK

    • Immune sera and immunoglobulins
    Contract value
    £1
    Annual run-rate
    £1value ÷ published term
    Term
    1 May 2025 → 30 Apr 2027 · 1.9 yrs
    Reference
    ocds-h6vhtk-047b9e
  25. Ends · in 230 daysFramework re-letExtension option · up to 31 May 2029Panel · 5 suppliers

    Lot 2 - CM/PHS/25/5728/02

    NHS England · Central government · Nationwide (UK), North East England, North West England, Yorkshire and the Humber, East Midlands, West Midlands

    Panel: Bayer Plc, Biosimilar Collaborations Ireland Limited, Celltrion Healthcare Uk Ltd +2 more

    • Pharmaceutical products
    • Various medicinal products
    Contract value
    £783mceiling for the whole framework
    Annual run-rate
    —panel, not one supplier
    Term
    1 Dec 2025 → 31 May 2027 · 1.4 yrs · up to 31 May 2029 with extensions
    Reference
    ocds-h6vhtk-055064
How to read the radar
  • End date is the contract period end the buyer published on Find a Tender. Contracts without an end date are not on the radar.
  • Extension option means the notice publishes a renewal or option clause; the buyer may extend instead of retendering. Hide them to see contracts that must be re-procured.
  • Incumbent is the canonical supplier on the award behind the contract. A panel (several suppliers on one award) is shown as a panel — no single incumbent is invented.
  • Annual run-rate = published GBP value ÷ published term, only for a single supplier, a term of six months or more and a plain contract (not a framework or DPS ceiling).
  • Counts are exact from the nightly projection when you filter by horizon and sector only; any other filter shows a bounded total — exact up to 1,000 contracts, an honest “1,000+” floor above that.